Characteristics of Included Studies. TRIPOD statement: a preliminary pre-post analysis of reporting and methods of prediction models The PubMed search string retrieved 481 articles, of which the full-text of 119 were read and 70 met our inclusion criteria (pre-TRIPOD: 32 articles, post-TRIPOD: 38 articles, Figure 1, Supplementary Text 1). Most of the included articles were published in The BMJ (n=38), and least in The Lancet (n=3) and NEJM (n=1). In both the pre- and post-TRIPOD period the majority of articles described prognostic models (as opposed to diagnostic models) and this increased in the post-TRIPOD period (pre-TRIPOD: 59%, post-TRIPOD: 89%) (Table 2). In the post-TRIPOD period the percentage of articles describing both the development and validation of a model (pre-TRIPOD: 31%, post-TRIPOD: 39%) or solely the external validation (pre-TRIPOD: 13%, post-TRIPOD: 26%) increased too. Thirty-two percent of articles only described the development of a prediction model without external validation in the post-TRIPOD period, compared to 44% in the pre-TRIPOD period. Diagnostic 13 (41%) 4 (11%) Prognostic 19 (59%) 34 (89%) Development 14 (44%) 12 (32%) Validation 4 (13%) 10 (26%) Development and Validation 10 (31%) 15 (39%) Update 4 (13%) 1 (3%) General population and Primary care 18 (56%) 18 (47%) Secondary care 14 (44%) 20 (53%) Cohort 26 (81%) 31 (82%) RCT 1 (30%) 4 (11%) Cohort and RCT 2 (6%) 3 (8%) Case-Control 3 (9%) 0 (0%) (Cardio)vascular 12 (38%) 16 (42%) Oncological 3 (9%) 8 (21%) Other 17 (53%) 14 (37%) Chapter 7 The majority of models were developed and/or validated using data from observational cohorts (pre-TRIPOD: 81%, post-TRIPOD: 82%) compared to other study designs such as randomised trials. More than half of the articles published in the post-TRIPOD period referred to the TRIPOD Statement (n=20, 53%) and were published in journals that published the TRIPOD Statement (n=21, 55%). The TRIPOD Statement was cited in 48% of articles published in journals that published the TRIPOD, and in 59% of articles in journals that did not publish TRIPOD.

Characteristics of Included Studies. Among the included studies, all were published on or after 2005, and analyzed data collected as early as 1991 (Table 2). Most of the studies were secondary analyses of Demographic and Health Surveys (DHS) (n=11) conducted in urban and rural settings in lower-middle income countries (n=8) and representative of two major geographical regions: Africa (n=4) and South-Asia (n=7). In addition, one African multi-country review was included. India was the most frequently represented country in the review (n=5), followed by Nigeria (n=3). The sample sizes ranged from around 1,000 to approximately 15,000 respondents. The most common method of analysis used by the authors was multivariate logistic regression (42%), with the remainder employing multilevel, stepwise or bivariate regression analysis. Only two of the studies included a theoretical framework that addressed both empowerment and immunization coverage. The most common age range for reporting immunization outcomes was 12-23 months (n=6, Table 2). In general, the authors defined agency in diverse ways, most frequently “autonomy” (50%) and “empowerment” (17%). The items used to measure agency fell into three domains: decision-making, freedom of movement, and other (Table 3). Several reoccurring themes persisted across these items: health decisions of the woman, financial control, permission to go/ visit health centers, friends and family as well as large and daily household purchases. Across all studies, the most common measures of women’s agency were measures based on decision-making items (58%, Table 2). These studies used a total of 13 different DM items (Table 3), only two used DM items pertaining to a woman’s ability to decide to go to a health facility: “can go to the local health center without seeking permission”(DM 2, Table 3) and “decisions to go to a health facility” (DM 8, Table 3). Moreover, only one item specifically connected the mother to the child’s health by asking who was “the main decision-maker when the child is ill” (DM 1, Table, 3). Otherwise, the remaining DM items pertained to decisions regarding household purchases, ability to move and see friends, family, or relatives, finances, and health (Table 3). Less emphasis was placed on measuring agency with freedom-of-movement items only (without measuring decision-making) (n=2, Table 3). Both of the studies that included freedom-of- movement items analyzed data from India [17,20]. Many of the authors operationalized freedom of movement in ut...

Characteristics of Included Studies. Presented in Table 3 is the summary of the main characteristics of each study included in the systematic review and meta-analyses. The *next to the authors name denotes studies that were included in the meta-analysis. The subscript a next to the authors name signifies that studies contained the same HC comparison group. The column headed ‘Outcome of Measure’ gives a description of the comparison of the ES between clinical group and control group. The column titled ‘Group and N’ shows which patient group (e.g. AN, BN, ED) is being compared to the control group. For example the study by Chassler (1997) compares attachment between ED and controls. The table does not give a comparison between two clinical groups. Self-report instruments were used mainly to assess the areas of ‘Affiliation and attachment’, Self- Evaluation’ and ‘Social Dominance’, while experimental tasks were primarily used to test the areas of ‘Reception of Facial Communication’, ‘Production of Facial Communication’, ‘Reception of Non-Facial Communication’, ‘Agency’ and ‘Understanding Mental States’. Only in the area of ‘Production of Non-Facial Communication’, was there the same number of self-report and experimental tasks. The majority of studies investigated a sample of individuals with a current diagnosis of AN. Studies Group and N Age: mean (sd) BMI (sd) Co-morbidity Measure Outcome of measure Xxxxx’x d (95% C.I.) ‘Affiliation and Attachment’ *Amianto et al. (2011) AN 38 26.31 (7.4) 16.42 (2.0) NR Attachment Style Questionnaire Parental Bonding Instrument Insecurity Lower security Lower Parental Care Higher Parental Overprotection 0.779 (0.335, 1.223) 0.981 (0.534, 1.427) 0.900 (0.457, 1.343) 1.229 (0.768, 1.689) HC 50 23.95 (2.1) 21.86 (2.7) - *Bonne (2003) BN 16 23 (2) 19.96 NR Parental Bonding Instrument Lower Parental Care Higher Parental Overprotection 0.803 (0.081, 1.525) 0.254 (-0.441, 0.950) HC 16 23 (2) 19.96 - *Bulik et al. (2000) AN 15 AN-Rec 21 23-45 18.5 (2.6) NR Parental Bonding Instrument Lower Parental Care Higher Parental Overprotection 1.123 (0.560, 1.686) 0.408 (-0.066, 0.883) 0.379 (-0.167, 0.925) 0.496 (0.020, 0.972) HC 98 23-45 25.6 (6.5) - *Calam et al. (2006) AN 31 BN 67 25 - NR Parental Bonding Instrument Lower Parental Care Higher Parental Overprotection 0.104 (-0.270, 0.478) 0.438 (0.166, 0.711) 0.266 (-0.108, 0.641) 0.190 (-0.081, 0.461) HC 242 22.9 - - *Xxxxxxx et al. (2008) AN 43 21.3 (3.7) 16.7 (2.1) 5 depressive disorder Parental Bonding Instrument Lower P...

Characteristics of Included Studies. The majority of the studies were conducted in the USA (n = 8) with one study conducted in England. Five used a wider area which included participants from more rural settings, and four related to a single city and were restricted to urban areas. Most of the studies used adult samples (n = 8) and one used a sample of juvenile offenders. Of the studies in the USA, two recruited samples from jails, three from state prisons and three from mixed correctional facilities. The prison system operates in a different way and the study in England recruited from remand prisons. None of the studies were restricted to a single disorder and criteria for inclusion in the studies ranged from solely being diagnosed with a mental health problem, being treated by a mental health team within the prison, being adjudged to be of high risk, or being homeless before entry into custody. Four studies were based on cohorts, either from facilities that did not offer the intervention or from a time when the intervention was not available in the same facility. Two studies were randomised controlled trials. Two were case series with no comparison group and one used a pre-post comparison with outcomes compared to the same time period before contact with the program. Study outcomes ranged from contact with health services (n = 2), Medicaid enrolment (n = 1), recidivism (n = 4), sanctions for treatment non-compliance (n = 1) and place of residence at time of treatment discharge. Most of the studies were bridging interventions, with intervention provided both before and after release, but there were also examples of care only in the pre (n = 1) or post (n = 2) release period. The majority of the interventions used a mixed approach (n = 8) with case management, psychosocial modules and onward referral represented. The other study focused on Medicaid enrolment (n = 1). In the majority of cases, the intervention was delivered by a clinician (n = 7) and in two the required qualifications were not reported. Table 1 gives a more detailed description of the interventions used in each study. Included Eligibility Full-text articles excluded, (n = 36) - Conference proceeding (6) - Not data based (4) - No intervention (7) - Not aimed at transition (7) - Not prison (4) - Not mental health problems (8) Records excluded (n = 9094) Records screened (n = 9140) Screening Identification

Characteristics of Included Studies. The included studies varied in quality, as seen in Table 1, with many having fair to poor quality due to a reliance on self-reports to ascertain variables of interest and a lack of statistical control for confounding factors in the analyses of effect sizes. However, all studies were included in the meta-analysis given the small number of studies relating physical disability to postpartum depression that were identified by the screening process. The summary characteristics of the studies are presented in Table 2, the study demographics are presented in Table 3, and the study characteristics are presented in Table 4.

Characteristics of Included Studies

Related to Characteristics of Included Studies

Statistical Sampling Documentation a. A copy of the printout of the random numbers generated by the “Random Numbers” function of the statistical sampling software used by the IRO.‌ b. A description or identification of the statistical sampling software package used by the IRO.‌
Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.
Regulatory Activities Beginning on the Effective Date and to the extent UGNX remains the Lead Development Party with respect to a particular territory, subject to and in accordance with the terms and conditions of this Agreement and the requirements of Applicable Laws, UGNX, shall: (a) use Commercially Reasonable Efforts to file (or have filed) all Regulatory Filings with respect to the Licensed Products in the Field in order to obtain Marketing Approvals in each country in the Territory and the European Territory (or to obtain the European Centralized Approval in the European Core Territory) and in order to obtain Pricing and/or Reimbursement Approvals in the Profit Share Territory; (b) respond in a timely fashion to requests for data and information from Regulatory Authorities with respect to the Licensed Products in the Field in the Territory and the European Territory; and (c) meet with officials of the Regulatory Authorities at such times as may be requested by such Regulatory Authorities with respect to the Core Development Activities (“Regulatory Activities”), provided that KHK will have primary responsibility for obtaining, and UGNX shall provide all assistance reasonably requested by KHK, in relation to Pricing and/or Reimbursement Approvals for the Licensed Products in the Field in the European Territory. For the avoidance of doubt, UGNX will be responsible for obtaining, and KHK will provide all assistance reasonably requested by UGNX, in relation to Pricing and/or Reimbursement Approvals, if any, for the Licensed Products in the Field in the Profit Share Territory as part of the UGNX Core Development Activities, it being understood that the costs incurred by UGNX in connection with such activities will be shared equally (50/50). All such Regulatory Activities will be conducted in a manner consistent with the Core Development Plan and coordinated by the JSC in accordance with Article 3. Without limiting the applicability of the foregoing and the remainder of this Article 5, UGNX shall interface with the applicable Regulatory Authority(ies) and, through the JDC, shall keep KHK reasonably informed of all material events and developments occurring in the course of the Regulatory Activities, including scheduled UGNX regulatory strategy discussions and meetings with Regulatory Authorities in the Territory and the European Territory relating to the Licensed Products in the Field.
Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.
Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.
Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to the U.S. Food and Drug Administration (the “FDA”) or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.
Environmental Studies Promptly conduct and complete, at Borrower’s expense, all such investigations, studies, samplings and testings as may be requested by Lender or any governmental authority relative to any substance, or any waste or by-product of any substance defined as toxic or a hazardous substance under applicable federal, state, or local law, rule, regulation, order or directive, at or affecting any property or any facility owned, leased or used by Borrower.
Investment Analysis and Implementation In carrying out its obligations under Section 1 hereof, the Advisor shall: (a) supervise all aspects of the operations of the Funds; (b) obtain and evaluate pertinent information about significant developments and economic, statistical and financial data, domestic, foreign or otherwise, whether affecting the economy generally or the Funds, and whether concerning the individual issuers whose securities are included in the assets of the Funds or the activities in which such issuers engage, or with respect to securities which the Advisor considers desirable for inclusion in the Funds' assets; (c) determine which issuers and securities shall be represented in the Funds' investment portfolios and regularly report thereon to the Board of Trustees; (d) formulate and implement continuing programs for the purchases and sales of the securities of such issuers and regularly report thereon to the Board of Trustees; and (e) take, on behalf of the Trust and the Funds, all actions which appear to the Trust and the Funds necessary to carry into effect such purchase and sale programs and supervisory functions as aforesaid, including but not limited to the placing of orders for the purchase and sale of securities for the Funds.
Adverse Events Subsequent to the date hereof, there shall not have occurred any of the following: (i) a suspension or material limitation in trading in securities generally on the New York Stock Exchange, the NASDAQ National Market or the NASDAQ Global Market, (ii) a general moratorium on commercial banking activities in the People’s Republic of China or New York, (iii) the outbreak or escalation of hostilities involving the United States or the People’s Republic of China or the declaration by the United States or the People’s Republic of China of a national emergency or war if the effect of any such event specified in this clause (iii) in your reasonable judgment makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares on the terms and in the manner contemplated in the Prospectus, or (iv) such a material adverse change in general economic, political, financial or international conditions affecting financial markets in the United States or the People’s Republic of China having a material adverse impact on trading prices of securities in general, as, in your reasonable judgment, makes it impracticable or inadvisable to proceed with the public offering of the Shares or the delivery of the Shares on the terms and in the manner contemplated in the Prospectus.
Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

Characteristics of Included Studies Sample Clauses

Filter & Search

Related Clauses

Parent Clauses

Sub-Clauses

Related to Characteristics of Included Studies